1354696-56-2

Upstream product

• 52867-42-2 5-hydroxy-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester 
• 1354696-65-3 8-(3-{[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy}-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-7-{[2-(trimethylsilanyl)ethoxy]methyl}-3,7-dihydro-1H-purine-2,6-dione 
• 1354696-64-2 8-(3-hydroxy-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-3,7-dihydro-1H-purine-2,6-dione 
• 175205-62-6 5-[(3-methoxy)phenyl]-3-chloromethyl-1,2,4-oxadiazole 
• 1354696-63-1 8-[(3-benzyloxy)-1-methyl-1H-pyrazol-5-yl]-1,3-dipropyl-7-(2-(trimethylsilanyl)ethoxymethyl)-3,7-dihydro-purine-2,6-dione 
• 1354696-62-0 8-[3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl]-1,3-dipropyl-3,7-dihydro-1H-purine-2,6-dione 
• 628329-62-4 methyl 3-(benzyloxy)-1-methyl-1H-pyrazole-5-carboxylate 
• 1313389-24-0 3-(benzyloxy)-1-methyl-1H-pyrazole-5-carboxylic acid 

Relevant academic research and scientific papers

Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl) xanthines as potent and selective A2B adenosine receptor antagonists

Molecular modeling studies, including the comparative molecular field analysis (CoMFA) method, on 52 antagonists of the A2B adenosine receptor with known biological activity were performed to identify the three-dimensional features responsible